The EED protein-protein interaction inhibitor A-395 inactivates the PRC2 complex.

Polycomb repressive complex 2 (PRC2) is a regulator of epigenetic states required for development and homeostasis. PRC2 trimethylates histone H3 at lysine 27 (H3K27me3), which leads to gene silencing, and is dysregulated in many cancers. The embryonic ectoderm development (EED) protein is an essential subunit of PRC2 that has both a scaffolding function and an H3K27me3-binding function. Here we report the identification of A-395, a potent antagonist of the H3K27me3 binding functions of EED. Structural studies demonstrate that A-395 binds to EED in the H3K27me3-binding pocket, thereby preventing allosteric activation of the catalytic activity of PRC2. Phenotypic effects observed in vitro and in vivo are similar to those of known PRC2 enzymatic inhibitors; however, A-395 retains potent activity against cell lines resistant to the catalytic inhibitors. A-395 represents a first-in-class antagonist of PRC2 protein-protein interactions (PPI) for use as a chemical probe to investigate the roles of EED-containing protein complexes.

[1]  Tim J. Wigle,et al.  Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 , 2013, Proceedings of the National Academy of Sciences.

[2]  L. Pasqualucci.  Diffuse Large B-Cell Lymphoma , 2013 .

[3]  Joshua M. Korn,et al.  Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors , 2015, Oncogene.

[4]  C. Tse,et al.  The Histone Methyltransferase Inhibitor A-366 Uncovers a Role for G9a/GLP in the Epigenetics of Leukemia , 2015, PloS one.

[5]  Joseph D. Kwasnoski,et al.  High-density miniaturized thermal shift assays as a general strategy for drug discovery. , 2001, Journal of biomolecular screening.

[6]  E. Chan,et al.  Identification of EZH2 and EZH1 small molecule inhibitors with selective impact on diffuse large B cell lymphoma cell growth. , 2013, Chemistry & biology.

[7]  P. Steigemann,et al.  EZH2 Inhibition Blocks Multiple Myeloma Cell Growth through Upregulation of Epithelial Tumor Suppressor Genes , 2015, Molecular Cancer Therapeutics.

[8]  C. James,et al.  The histone H 3 . 3 K 27 M mutation in pediatric glioma reprograms H 3 K 27 methylation and gene expression , 2013 .

[9]  G. Murshudov,et al.  Refinement of macromolecular structures by the maximum-likelihood method. , 1997, Acta crystallographica. Section D, Biological crystallography.

[10]  Y. Schwartz,et al.  A new world of Polycombs: unexpected partnerships and emerging functions , 2013, Nature Reviews Genetics.

[11]  M. Vidal,et al.  Role of histone H2A ubiquitination in Polycomb silencing , 2004, Nature.

[12]  Jon R. Wilson,et al.  Structural basis of oncogenic histone H3K27M inhibition of human polycomb repressive complex 2 , 2016, Nature Communications.

[13]  Amber L. Couzens,et al.  (R)-PFI-2 is a potent and selective inhibitor of SETD7 methyltransferase activity in cells , 2014, Proceedings of the National Academy of Sciences.

[14]  K Henrick,et al.  Electronic Reprint Biological Crystallography Secondary-structure Matching (ssm), a New Tool for Fast Protein Structure Alignment in Three Dimensions Biological Crystallography Secondary-structure Matching (ssm), a New Tool for Fast Protein Structure Alignment in Three Dimensions , 2022 .

[15]  Guo-Cheng Yuan,et al.  EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. , 2008, Molecular cell.

[16]  E. Lewis.  A gene complex controlling segmentation in Drosophila , 1978, Nature.

[17]  B. Garcia,et al.  Inhibition of PRC2 Activity by a Gain-of-Function H3 Mutation Found in Pediatric Glioblastoma , 2013, Science.

[18]  Jonathan Bard,et al.  Evaluation of fluorescence-based thermal shift assays for hit identification in drug discovery. , 2004, Analytical biochemistry.

[19]  Clemens Vonrhein,et al.  Data processing and analysis with the autoPROC toolbox , 2011, Acta crystallographica. Section D, Biological crystallography.

[20]  J. Martinez-Climent,et al.  Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma. , 2014, Blood.

[21]  M. Vedadi,et al.  Thermal denaturation assays in chemical biology. , 2012, Assay and drug development technologies.

[22]  R. Kingston,et al.  The Core of the Polycomb Repressive Complex Is Compositionally and Functionally Conserved in Flies and Humans , 2002, Molecular and Cellular Biology.

[23]  Chao Xu,et al.  Binding of different histone marks differentially regulates the activity and specificity of polycomb repressive complex 2 (PRC2) , 2010, Proceedings of the National Academy of Sciences.

[24]  Juri Rappsilber,et al.  A model for transmission of the H3K27me3 epigenetic mark , 2008, Nature Cell Biology.

[25]  Robert E. Kingston,et al.  Mechanisms of Polycomb gene silencing: knowns and unknowns , 2009, Nature Reviews Molecular Cell Biology.

[26]  D. Reinberg,et al.  Role of the polycomb protein EED in the propagation of repressive histone marks , 2009, Nature.

[27]  N. Harris,et al.  EZH2 Codon 641 Mutations are Common in BCL2-Rearranged Germinal Center B Cell Lymphomas , 2011, PloS one.

[28]  William B. Smith,et al.  Selective inhibition of BET bromodomains , 2010, Nature.

[29]  Ryan D. Morin,et al.  Somatic mutation of EZH2 (Y641) in Follicular and Diffuse Large B-cell Lymphomas of Germinal Center Origin , 2010, Nature Genetics.

[30]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.

[31]  Kevin Cowtan,et al.  research papers Acta Crystallographica Section D Biological , 2005 .

[32]  Hengbin Wang,et al.  Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing , 2002, Science.

[33]  Yan Liu,et al.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations , 2012, Nature.

[34]  R. Copeland,et al.  Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas , 2010, Proceedings of the National Academy of Sciences.

[35]  J. Pritchard,et al.  Acquisition of a single EZH2 D1 domain mutation confers acquired resistance to EZH2-targeted inhibitors , 2015, Oncotarget.

[36]  K. Gajiwala,et al.  Polycomb repressive complex 2 structure with inhibitor reveals a mechanism of activation and drug resistance , 2016, Nature Communications.

[37]  Tim J. Wigle,et al.  A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. , 2012, Nature chemical biology.

[38]  D. Reinberg,et al.  Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. , 2002, Genes & development.

[39]  Steven J. M. Jones,et al.  Frequent mutation of histone modifying genes in non-Hodgkin lymphoma , 2011, Nature.

[40]  Sabine Mueller,et al.  The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. , 2013, Genes & development.

[41]  J. Squire,et al.  Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer , 2008, Current genomics.

[42]  G. Ganji,et al.  EZH 2 inhibition as a therapeutic strategy for lymphoma with EZH 2-activating mutations , 2012 .

[43]  S. Ogawa,et al.  EED mutants impair polycomb repressive complex 2 in myelodysplastic syndrome and related neoplasms , 2012, Leukemia.

[44]  S. Frye,et al.  The structure-activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface. , 2013, MedChemComm.

[45]  Xin Liu,et al.  Structural basis of histone H3K27 trimethylation by an active polycomb repressive complex 2 , 2015, Science.

[46]  M. Surani,et al.  The Polycomb-Group GeneEzh2 Is Required for Early Mouse Development , 2001, Molecular and Cellular Biology.

[47]  D. Reinberg,et al.  Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms. , 2008, Molecular cell.

[48]  P. Steigemann,et al.  EZH 2 inhibition blocks multiple myeloma cell growth through upregulation of epithelial tumor suppressor genes , 2015 .

[49]  K. Helin,et al.  Transcriptional regulation by Polycomb group proteins , 2013, Nature Structural &Molecular Biology.

[50]  Victor S. Lobanov,et al.  High-Density Miniaturized Thermal Shift Assays as a General Strategy for Drug Discovery , 2001 .

[51]  K. Hahn,et al.  An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1. , 2013, ACS chemical biology.

[52]  C. Bountra,et al.  Epigenetic protein families: a new frontier for drug discovery , 2012, Nature Reviews Drug Discovery.

[53]  Yong Jiang,et al.  Mutation of A677 in histone methyltransferase EZH2 in human B-cell lymphoma promotes hypertrimethylation of histone H3 on lysine 27 (H3K27) , 2012, Proceedings of the National Academy of Sciences.

[54]  Shili Duan,et al.  Recognition and Specificity Determinants of the Human Cbx Chromodomains* , 2010, The Journal of Biological Chemistry.

[55]  Jean-François Couture,et al.  Molecular recognition of histone H3 by the WD40 protein WDR5 , 2006, Nature Structural &Molecular Biology.

[56]  F. Niesen,et al.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.

[57]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[58]  T. Magnuson,et al.  The eed mutation disrupts anterior mesoderm production in mice. , 1995, Development.

[59]  Yi Zhang,et al.  Role of Bmi-1 and Ring1A in H2A ubiquitylation and Hox gene silencing. , 2005, Molecular cell.

[60]  Kristian Helin,et al.  The Polycomb Group Protein Suz12 Is Required for Embryonic Stem Cell Differentiation , 2007, Molecular and Cellular Biology.